Literature DB >> 10565847

Discriminative stimulus effects of zolpidem in squirrel monkeys: comparison with conventional benzodiazepines and sedative-hypnotics.

J K Rowlett1, R D Spealman, S Lelas.   

Abstract

The present study examined whether zolpidem, an imidazopyridine with selectivity for benzodiazepine (BZ)/gamma-aminobutyric acid(A) receptors containing the alpha1-subunit, had discriminative stimulus effects similar to typical BZs and other sedative/hypnotic drugs in primates. Squirrel monkeys (Saimiri sciureus) were trained to discriminate zolpidem (1.0 mg/kg i.v.) from vehicle under a 10-response fixed-ratio schedule of food delivery. Under test conditions, zolpidem (0.1-3.0 mg/kg) increased responding on the drug lever to an average maximum of 90% of total responding. When pretreatment times were varied from 5 to 50 min, the discriminative stimulus effects of zolpidem were maximal at 5 min and near control levels 35 min after administration. Flumazenil antagonized both the discriminative stimulus and rate-decreasing effects of zolpidem in a dose-dependent and surmountable fashion (in vivo apparent pA(2) values of 7.3 and 6.6 for the discriminative stimulus and rate-suppressing effects, respectively). The BZs triazolam, midazolam, diazepam, and N-desmethyldiazepam engendered dose-related increases in drug-lever responding that reached zolpidem-like levels (90%) in the majority of monkeys tested. In contrast, lorazepam, chlordiazepoxide, and oxazepam engendered average maximums of 70% or less and substituted fully for zolpidem in one or two monkeys only. Representative barbiturates as well as drugs that bind to non-BZ sites (muscimol, baclofen, buspirone, cyproheptadine, diphenhydramine) engendered 0 to 45% of responses on the drug lever up to doses that markedly reduced response rate. These results support the view that zolpidem's selectivity for the alpha1-subunit of the BZ/gamma-aminobutyric acid(A) receptor complex confers a distinctive profile of interoceptive effects that overlaps partially with those of typical BZs but not with those of barbiturates.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10565847

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Comparing the discriminative stimulus effects of modulators of GABAA receptors containing α4-δ subunits with those of gaboxadol in rats.

Authors:  Claudio Zanettini; Jeffrey D Pressly; Miguel H Ibarra; Kelsey R Smith; Lisa R Gerak
Journal:  Psychopharmacology (Berl)       Date:  2016-02-22       Impact factor: 4.530

Review 2.  The behavioral pharmacology of zolpidem: evidence for the functional significance of α1-containing GABA(A) receptors.

Authors:  Amanda C Fitzgerald; Brittany T Wright; Scott A Heldt
Journal:  Psychopharmacology (Berl)       Date:  2014-02-22       Impact factor: 4.530

Review 3.  Principles of laboratory assessment of drug abuse liability and implications for clinical development.

Authors:  Lawrence P Carter; Roland R Griffiths
Journal:  Drug Alcohol Depend       Date:  2009-05-14       Impact factor: 4.492

4.  Zolpidem generalization and antagonism in male and female cynomolgus monkeys trained to discriminate 1.0 or 2.0 g/kg ethanol.

Authors:  Christa M Helms; Laura S M Rogers; Courtney A Waters; Kathleen A Grant
Journal:  Alcohol Clin Exp Res       Date:  2008-07       Impact factor: 3.455

5.  Discriminative stimulus effects of L-838,417 (7-tert-butyl-3-(2,5-difluoro-phenyl)-6-(2-methyl-2H-[1,2,4]triazol-3-ylmethoxy)-[1,2,4]triazolo[4,3-b]pyridazine): role of GABA(A) receptor subtypes.

Authors:  Stephanie C Licata; Donna M Platt; Daniela Rüedi-Bettschen; John R Atack; Gerard R Dawson; Michael L Van Linn; James M Cook; James K Rowlett
Journal:  Neuropharmacology       Date:  2009-10-22       Impact factor: 5.250

6.  The Somatostatin Receptor-4 Agonist J-2156 Alleviates Mechanical Hypersensitivity in a Rat Model of Breast Cancer Induced Bone Pain.

Authors:  Priyank A Shenoy; Andy Kuo; Nemat Khan; Louise Gorham; Janet R Nicholson; Laura Corradini; Irina Vetter; Maree T Smith
Journal:  Front Pharmacol       Date:  2018-05-15       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.